



GENENTECH

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hsei et al.

) Group Art Unit 1644

Appl. No. : 09/234,182

) I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first-class mail in
an envelope addressed to: United States Patent
and Trademark Office, P.O. Box 2327,
Arlington, VA 22202, on

Filed : January 20, 1999

) October 17, 2002
(Date)For : ANTIBODY FRAGMENT-
POLYMER CONJUGATES
AND HUMANIZED ANTI-IL-8
MONOCLONAL ANTIBODIES

) Ginger R. Dreyer, Reg. No. 33,065

Examiner : ROARK, JESSICA H.United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

RECEIVED

Dear Sir:

TECH. CIVILIAN 1600-2900

In response to the Office Action, mailed on May 20, 2002 (Paper No. 23), setting a three-months term, please consider the following remarks and amendments.

In the Specification:

Please amend the title to read as follows:

~~ANTIBODY FRAGMENT-POLYMER CONJUGATES~~

Please amend the paragraph beginning at page 206, line 1, with following new paragraph:

--Production of a F(ab')₂ version of the humanized anti-IL-8 6G4V11N35A Fab was accomplished by constructing a fusion protein with the yeast GCN4 leucine zipper. The expression plasmid p6G4V11N35A.F(ab')₂ was made by digesting the plasmid p6G425chim2.fab2 with the restriction enzymes bsal and apal to remove the DNA sequence encoding the 6G4.2.5 murine-human chimeric Fab and replacing it with a 2620bp bsal-apal